Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 versus empagliflozin and glimepiride as add-on to metformin in type 2 diabetes
2016-001165-88Phase 3Terminated
- Sponsor
- Intarcia Therapeutics
- Start
- Apr 2017
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing ITCA 650 add-on to metformin, Empagliflozin add-on to metformin and Glimepiride add-on to metformin (3 arms). Primary endpoints: Glycated hemoglobin reduction at 65 weeks and Body weight change at 65 weeks. Started Apr 2017; status: terminated.
02
Drugs
ITCA 650empagliflozinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001165-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001165-88.